Skip to content

Determining the subjective effects of TFMPP in human males.

Reem K Jan, Joanne C Lin, HeeSeung Lee, Janie L Sheridan, Rob R Kydd, Ian J. Kirk, Bruce R. Russell

Psychopharmacology August 2010 DOI: 10.1007/s00213-010-1911-y (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Placebo-controlled Double-blind Peer reviewed
Sample size 30
Population Healthy, non-smoking male volunteers, mean age 24 +/- 4 years
Intervention TFMPP
Dose 60 mg
Measures Addiction Research Centre Inventory (ARCI), Profile of Mood States (POMS), Visual Analogue Scales (VAS)
Key findings TFMPP 60 mg produced increases in 'dysphoria', 'dexamphetamine-like effects', 'tension/anxiety', 'confusion/bewilderment', 'drug liking', 'high', and 'stimulated' ratings relative to placebo, suggesting a profile resembling amphetamine-type stimulants and serotonergic drugs.

Abstract

Trifluoromethylphenyl piperazine (TFMPP) is an active constituent of a relatively new group of recreational drugs known as 'party pills'. TFMPP has been anecdotally reported to induce mild psychedelic effects similar to lysergic acid diethylamide and psilocybin. There has been no research about the subjective effects of TFMPP in humans. This study aimed to investigate the subjective effects of TFMPP in human males. A randomised, double-blind, placebo-controlled trial design was used to investigate the subjective effects of TFMPP in 30 healthy, non-smoking male volunteers (mean age 24 +/- 4 years). Participants were randomised into two groups and given either TFMPP 60 mg (n = 15) or placebo (n = 15). Each participant completed three rating scales, the Addiction Research Centre Inventory (ARCI), the Profile of Mood States (POMS) and the Visual Analogue Scales (VAS), both before and 120 min after drug administration. Results from the ARCI indicated that TFMPP produced increases in 'dysphoria' and 'dexamphetamine-like effects'. TFMPP also increased ratings of 'tension/anxiety' and 'confusion/bewilderment' as rated on the POMS. Results from the VAS indicated increases in 'drug liking', 'high' and 'stimulated' ratings relevant to placebo. Increased ratings of 'dexamphetamine-like effects', 'tension/anxiety', 'stimulated' and 'high' following TFMPP administration resemble the subjective effects of common amphetamine-type stimulants. However, increases in 'dysphoria' and 'confusion/bewilderment' ratings following TFMPP are more commonly associated with drugs that have greater effects on serotonin release, binding and reuptake such as 1-[3-chlorophenyl]-piperazine, fenfluramine and lysergic acid diethylamide.

Citations in the library

Explore topics